Inxight Drugs

Search results for "Pharmacologic Substance[C1909]|Photosensitizing Agent" in comments (approximate match)

Showing 1 - 10 of 22 results

HEXAMINOLEVULINATE

MORE DETAILS

G7H20TKI67

Status:

US Approved Rx (2010)

First approved in 2010

Class (Stereo):

CHEMICAL (ACHIRAL)

Conditions:

Hexaminolevulinate is an optical imaging drug. In solution form, it is instilled intravesically for use with photodynamic blue light cystoscopy as an adjunct to white light cystoscopy. After bladder instillation, hexaminolevulinate enters the bladder...

AMINOLEVULINIC ACID

MORE DETAILS

88755TAZ87

Status:

US Approved Rx (2016)

First approved in 1995

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Aminolevulinic Acid is the first compound in the porphyrin synthesis pathway. The metabolism of aminolevulinic acid (ALA) is the first step in the biochemical pathway resulting in heme synthesis. Aminolevulinic acid is not a photosensitizer, but rat...

her a metabolic precursor of protoporphyrin IX (PpIX), which is a photosensitizer. The synthesis of ALA is normally tightly controlled by feedback inhibition of the enzyme, ALA synthetase, presumably by intracellular heme levels. ALA, when provided to the cell, bypasses this control point and results in the accumulation of PpIX, which is converted into heme by ferrochelatase through the addition of iron to the PpIX nucleus. Marketed under the brand name LEVULAN KERASTICK for Topical Solution plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator, it is indicated for the treatment of minimally to moderately thick actinic keratoses (Grade 1 or 2, see table 2 for definition) of the face or scalp. Aminolevulinic acid is also being studied in the treatment of other conditions and types of cancer. An orally-administered in vivo diagnostic agent, Aminolevulinic acid, is used in photodynamic diagnosis (PDD) whose aim is to help doctors visualize the tumor tissue during surgical resection of malignant glioma, it is already sold in over 20 European countries including Germany and the U.K. According to the presumed mechanism of action, photosensitization following application of aminolevulinic acid (ALA) topical solution occurs through the metabolic conversion of ALA to protoporphyrin IX (PpIX), which accumulates in the skin to which aminolevulinic acid has been applied. When exposed to light of appropriate wavelength and energy, the accumulated PpIX produces a photodynamic reaction, a cytotoxic process dependent upon the simultaneous presence of light and oxygen. The absorption of light results in an excited state of the porphyrin molecule, and subsequent spin transfer from PpIX to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Photosensitization of actinic (solar) keratosis lesions using aminolevulinic acid, plus illumination with the BLU-UTM Blue Light Photodynamic Therapy Illuminator (BLU-U), is the basis for aminolevulinic acid photodynamic therapy (PDT).

METHOXSALEN

MORE DETAILS

U4VJ29L7BQ

Status:

US Approved Rx (2014)

First approved in 1954

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Methoxsalen — also called xanthotoxin, marketed under the trade names Oxsoralen, Deltasoralen, Meladinine — is a drug used to treat psoriasis, eczema, vitiligo, and some cutaneous lymphomas in conjunction with exposing the skin to UVA light from lamp...

s or sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, allegedly clearing up the disease. The dosage comes in 10 mg tablets, which are taken in the amount of 30 mg 75 minutes before a PUVA (psoralen + UVA) light treatment. Chemically, methoxsalen belongs to a class of organic natural molecules known as furanocoumarins. They consist of coumarin annulated with furan. It can also be injected and used topically. The exact mechanism of action of methoxsalen with the epidermal melanocytes and keratinocytes is not known. The best known biochemical reaction of methoxsalen is with DNA. Methoxsalen, upon photoactivation, conjugates and forms covalent bonds with DNA which leads to the formation of both monofunctional (addition to a single strand of DNA) and bifunctional adducts (crosslinking of psoralen to both strands of DNA) Reactions with proteins have also been described. Methoxsalen acts as a photosensitizer. Administration of the drug and subsequent exposure to UVA can lead to cell injury. Orally administered methoxsalen reaches the skin via the blood and UVA penetrates well into the skin. If sufficient cell injury occurs in the skin, an inflammatory reaction occurs. The most obvious manifestation of this reaction is delayed erythema, which may not begin for several hours and peaks at 48–72 hours. The inflammation is followed, over several days to weeks, by repair which is manifested by increased melanization of the epidermis and thickening of the stratum corneum. The mechanisms of therapy are not known. In the treatment of vitiligo, it has been suggested that melanocytes in the hair follicle are stimulated to move up the follicle and to repopulate the epidermis. In the treatment of psoriasis, the mechanism is most often assumed to be DNA photodamage and resulting decrease in cell proliferation but other vascular, leukocyte, or cell regulatory mechanisms may also be playing some role. Psoriasis is a hyperproliferative disorder and other agents known to be therapeutic for psoriasis are known to inhibit DNA synthesis. The most commonly reported side effect of methoxsalen alone is nausea, which occurs with approximately 10% of all patients. This effect may be minimized or avoided by instructing the patient to take methoxsalen with milk or food, or to divide the dose into two portions, taken approximately one-half hour apart. Other effects include nervousness, insomnia, and psychological depression.

LEMUTEPORFIN

MORE DETAILS

EZ109VJ012

Status:

Investigational

Class (Stereo):

CHEMICAL (UNKNOWN)

Lemuteporfin is a newly introduced, light-sensitive drug for use in combination photodynamic therapy (PDT). It acts on mitochrondria to initiate the apoptotic cascade resulting in cell death (apoptosis). The photosensitizer was highly potent, killing...

CIAFTALAN ZINC

MORE DETAILS

243KJ527MC

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Ciaftalan Zinc (also known as Zinc(II)-phthalocyanine) is phthalocyanine and photosensitizers which showed a high activity in photodynamic therapy studies on a variety of animal tumors. Ciaftalan Zinc belongs to second generation photosensitizers tha...

2-(1-HEXYLOXYETHYL)-2-DEVINYLPYROPHEOPHORBIDE A

MORE DETAILS

DOB7Y3RSX0

Status:

Investigational

Class (Stereo):

CHEMICAL (EPIMERIC)

2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH), a chlorin-based photosensitize, is used in photodynamic therapy. It has been shown the therapeutic potential of HPPH in phase II clinical trials for the treatment of esophageal cancer. Besides,...

ROSTAPORFIN

MORE DETAILS

466G63QE7G

Status:

Investigational

Class (Stereo):

CHEMICAL (RACEMIC)

Rostaporfin (SnET2, Purlytin, REM-001), a second generation photosensitizer drug, that was developed as part of Miravant's PhotoPoint photodynamic therapy (PDT) program, for the potential treatment of wet age-related macular degeneration (AMD). It wa...

CL-315585

MORE DETAILS

54JVX48G8K

Status:

Other

Class (Stereo):

CHEMICAL (RACEMIC)

METHYL AMINOLEVULINATE

MORE DETAILS

585NM85KYM

Status:

US Previously Marketed

First approved in 2004

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Conditions:

Methyl aminolevulinate is a prodrug that is metabolised to Protoporphyrin IX (a photosensitizer) used in photodynamic therapy. Photosensitization following application of methyl aminolevulinate cream occurs through the metabolic conversion of methyl ...

TALAPORFIN

MORE DETAILS

P4ROX5ELT2

Status:

Possibly Marketed Outside US

Class (Stereo):

CHEMICAL (ABSOLUTE)

Conditions:

Talaporfin (INN, also known as aspartyl chlorin, mono-L-aspartyl chlorin e6, NPe6, or LS11) is a photosensitizer used in photodynamic therapy (PDT). Talaporfin is injected into tumors and other regret tissues where it accumulates. It’s activated with...

Development Status

Primary Target

Highest Phase

Approval Year

Condition

Treatment Modality

CNS Activity

Originator

Substance Class

Code System

ATC Level 1

ATC Level 2

ATC Level 3

ATC Level 4

Substance Form

Search results for "Pharmacologic Substance[C1909]|Photosensitizing Agent" in comments (approximate match)

HEXAMINOLEVULINATE

G7H20TKI67

AMINOLEVULINIC ACID

88755TAZ87

METHOXSALEN

U4VJ29L7BQ

LEMUTEPORFIN

EZ109VJ012

CIAFTALAN ZINC

243KJ527MC

2-(1-HEXYLOXYETHYL)-2-DEVINYLPYROPHEOPHORBIDE A

DOB7Y3RSX0

ROSTAPORFIN

466G63QE7G

CL-315585

54JVX48G8K

METHYL AMINOLEVULINATE

585NM85KYM

TALAPORFIN

P4ROX5ELT2